TY - JOUR T1 - Gastric outlet obstruction with prostaglandin E1 infusion in congenital diaphragmatic hernia JF - Archives of Disease in Childhood - Fetal and Neonatal Edition JO - Arch Dis Child Fetal Neonatal Ed DO - 10.1136/archdischild-2021-323694 SP - fetalneonatal-2021-323694 AU - Andrea Togo AU - David Stewart AU - Amanda Moody AU - Sebastian King AU - Ruth K Armstrong Y1 - 2022/04/05 UR - http://fn.bmj.com/content/early/2022/04/05/archdischild-2021-323694.abstract N2 - Prostaglandin E1 (PGE1) is used globally in neonatal medicine to maintain patency of the ductus arteriosus in duct-dependent congenital heart disease. Due to its non-selective pulmonary vasodilator effect and its role in offloading the pressure on the right ventricle via the ductus arteriosus, PGE1 has been increasingly used in the management of neonatal pulmonary hypertension, especially in those patients with congenital diaphragmatic hernia (CDH).1 2 Gastric outlet obstruction (GOO) has been described as a side effect of PGE1 in populations with congenital heart disease, most commonly secondary to hypertrophic pyloric stenosis (HPS) or antral foveolar hyperplasia (AFH).3To describe our experience with the use of PGE1 in the CDH population and occurrence of GOO, we conducted a single-centre retrospective study of all … ER -